Class / Patent application number | Description | Number of patent applications / Date published |
514263340 |
Chalcogen bonded directly to the 2-and 6- positions of the purine ring system (e.g., theophylline, etc.)
| 69 |
514263310 |
With perservative, stabilizer, or an additional active ingredient
| 22 |
514263370 |
Nitrogen bonded directly to a ring carbon of the purine ring system (e.g., guanine, etc.)
| 15 |
514263330 |
Chalcogen bonded directly to the 2-,6-, and 8-positions of the purine ring system | 4 |
20090018148 | Xanthine Derivatives, Processes For Preparing Them And Their Uses - The present invention concerns xanthine derivatives, having formula (I), processes for preparing them, pharmaccutical compositions containing them and their use as pharmaceuticals. | 01-15-2009 |
20100105707 | METHOD OF TREATING OR PREVENTING OXIDATIVE STRESS-RELATED DISEASE - Disclosed is a method of treating or preventing an oxidative stress-related disease in a mammal in need thereof comprising administering an effective amount of a compound of formula (I) to the mammal, wherein R | 04-29-2010 |
20100234402 | METHODS AND COMPOSITIONS FOR TREATING SPINAL MUSCULAR ATROPHY - This invention provides methods of treating and abrogating spinal muscular atrophy by administering an antioxidant. Additionally, the invention provides a method of protecting the SMN protein by administering an antioxidant. | 09-16-2010 |
20120041006 | Compositions for Raising Uric Acid Levels and Methods of Using the Same - Compositions for the treatment of uric acid deficiency are disclosed. The compositions generally comprise either a precursor or derivative of uric acid, which, when administered to a patient, will result in a raising of the uric acid levels in that patient. The compositions can optionally comprise one or more additional active ingredients such as antioxidants, glutathione precursors, or inhibitors of NO synthase or homocysteine. Methods for raising uric acid levels in a patient are also disclosed. These methods are useful for in the treatment of various illnesses, such as cancer, infectious disease, Alzheimer disease and neurodegenerative diseases. Use of improved solutions comprising the present compositions in organ preservation is also disclosed. | 02-16-2012 |
Entries |
Document | Title | Date |
20080200482 | Use of a Partially Neutralized, Anionic (Meth)Acrylate Copolymer as a Coating for the Production of a Medicament Releasing Active Substance at Reduced Ph Values - (EN) The invention relates to the use of a partially neutralized, anionic (meth)acrylate copolymer comprising radically polymerized units of 25 to 95 percent by weight of C | 08-21-2008 |
20080214582 | Purine Derivatives as Inhibitors of Receptor Tyrosine Kinase Activity - Compounds of the formula (I), in which R | 09-04-2008 |
20080269258 | Riboswitches, Structure-Based Compound Design with Riboswitches, and Methods and Compositions for Use of and with Riboswitches - Riboswitches and modified versions of riboswitches can be employed as designer genetic switches that are controlled by specific effector compounds. Such effector compounds that activate a riboswitch are referred to herein as trigger molecules. The natural switches are targets for antibiotics and other small molecule therapies. In addition, the architecture of riboswitches allows actual pieces of the natural switches to be used to construct new non-immunogenic genetic control elements, for example the aptamer (molecular recognition) domain can be swapped with other non-natural aptamers (or otherwise modified) such that the new recognition domain causes genetic modulation with user-defined effector compounds. The changed switches become part of a therapy regimen-turning on, or off, or regulating protein synthesis. Newly constructed genetic regulation networks can be applied in such areas as living biosensors, metabolic engineering of organisms, and in advanced forms of gene therapy treatments. Compounds can be used to stimulate, active, inhibit and/or inactivate riboswitches. Atomic structures of riboswitches can be used to design new compounds to stimulate, active, inhibit and/or inactivate riboswitches. | 10-30-2008 |
20080280927 | 3-(DIHYDRO-1H-PYRAZOLO[4,3-D]PYRIMIDIN-5-YL)-4-PROPOXYBENZENESULFONAMIDE DERIVATIVES AND METHODS OF USE - This invention relates to novel 3-(dihydro-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-propoxybenzenesulfonamide compounds, their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering inhibitors of cyclic guanosine 3′,5′-monophosphate specific phosphodiesterase (cGMP-specific PDE), in particular PDE5. | 11-13-2008 |
20090042914 | Delayed release formulations of 6-mercaptopurine - The present invention provides enterically coated formulations of 6-mercaptopurine that exhibit a delay in release of the 6-mercaptopurine such that substantial release of 6-mercaptopurine does not occur until after passage through the stomach. Optionally, the formulations also comprise a delay coating in addition to the enteric coating that provides an even further delay such that substantial release of 6-mercaptopurine does not occur until after a certain period of time following passage through the stomach. Such a period of time is preferably at least one hour after passage through the stomach. Following the delay imparted by the enteric coating and optional delay coating, the formulations exhibit better bioavailability and faster dissolution than previous formulations. | 02-12-2009 |
20090118308 | 2,2-Bis-(hydroxymethyl)cyclopropylidenemethyl-Purines and -Pyrimidines As Antiviral Agents - Compounds which are active against viruses have the following formulas: | 05-07-2009 |
20090176810 | COMPOSITION FOR SKIN EXTERNAL APPLICATION CONTAINING GALLOCATECHIN GALLATE FOR MOISTURIZING EFFECT ON THE SKIN - The present invention relates to a composition for external skin application having a skin-moisturizing effect, which comprises gallocatechin gallate as an active ingredient. More particularly, the composition for external skin application comprises gallocatechin gallate as an active ingredient to activate peroxisome proliferator activated receptor isoform alpha (PPAR-α), to stimulate expression of filaggrin and involucrin that are skin-moisturizing factors, and thus to provide excellent anti-drying and skin-moisturizing effects. More particularly, the composition for external skin application may further comprise theobromine and quercetin in addition to gallocatechin gallate to maximize such effects. | 07-09-2009 |
20090264449 | HAIR CARE COMPOSITIONS AND METHODS FOR INCREASING HAIR DIAMETER - Disclosed in a hair care composition comprising: (i) a hair diameter increasing agent comprising a xanthine compound, a vitamin B3 compound, and a panthenol compound; and (ii) an carrier comprising water and monohydric alcohols having 1 to 6 carbons; wherein the monohydric alcohol is present in the composition at a level by weight of from about 10% to about 90%, preferably from about 30% to 90%, and wherein the composition may further comprises a substantially soluble silicone conditioning agent and/or a thickener. The hair care compositions of the present invention provide improved hair diameter increase benefit. The hair care compositions of the present invention also provide improved feel during usage and/or after usage, while not-compromising the penetration of the hair diameter increasing agent. | 10-22-2009 |
20100029692 | METHODS OF OPTIMIZING DRUG THERAPEUTIC EFFICACY FOR TREATMENT OF IMMUNE-MEDIATED GASTROINTESTINAL DISORDERS - The present invention provides a method of optimizing therapeutic efficacy and reducing toxicity associated with 6-mercaptopurine drug treatment of an immune-mediated gastrointestinal disorder such as inflammatory bowel disease. The method of the invention includes the step of determining the level of one or more 6-mercaptopurine metabolites in the patient having an immune-mediated gastrointestinal disorder. | 02-04-2010 |
20100184785 | PHARMACEUTICAL FORMULATION FOR THE PRODUCTION OF CHEWABLE TABLETS AND LOZENGES - The present invention relates to pharmaceutical formulations for the production of chewable and suckable tablets, comprising agglomerates based on sugar or sugar alcohols and disintegrant and water-insoluble polymers in combination with a viscosity-increasing/gel-forming polymer, and the corresponding chewable and suckable tablets. | 07-22-2010 |
20100204248 | MEDICAMENTS AND METHODS FOR INHIBITION OF NON-OCULAR SCARRING - Provided is the use of an agonist of a member of the nuclear hormone receptor NR4A subgroup in the manufacture of a medicament for the prevention, reduction or inhibition of scarring in a non-ocular tissue. Also provided is a method of preventing, reducing or inhibiting scarring in a non-ocular tissue, the method comprising administering a therapeutically effective amount of an agonist of a member of the nuclear hormone receptor NR4A subgroup to a patient in need of such prevention, reduction or inhibition. The NR4A agonist may be 6-mercaptopurine. The medicaments and methods may preferably be used to prevent, reduce or inhibit scarring in the skin. The medicaments and methods of the invention may be used to accelerate healing of wounds. | 08-12-2010 |
20110059994 | COMPOSITION FOR PREVENTING OR TREATING BRAIN CANCERS - A composition for preventing and/or treating brain tumor, containing caffeine and/or its analog, and/or their pharmaceutically acceptable salt, as an active ingredient, is provided. The composition for preventing or treating brain tumor has an activity to inhibit invasion, migration, and proliferation of brain tumor cells, and thereby very effective for the prevention and treatment of brain tumor. | 03-10-2011 |
20110086867 | 6-(C2-6ALKYLSELENO)PURINES AND METHODS FOR TREATING NEURAL MEASLES VIRAL INFECTION THEREWITH - The present application relates to anti-viral selenopurine compounds of formula (I): wherein R | 04-14-2011 |
20110105538 | DRUG RESPONSE MARKERS - The present invention relates to a method for predicting the response of a disease in a subject, preferably a human, to a drug providing 6-mercaptopurine, the method comprising the step of: (i) determining the presence or absence of a variant allele at a polymorphic site in a human leucocyte antigen (HLA)-G gene wherein the presence of said variant allele at said polymorphic site is indicative of clinical response or tolerance to said drug. The invention also provides a method of treating a subject suffering from a condition that would benefit from a drug providing 6-mercaptopurine. | 05-05-2011 |
20120190698 | METHODS OF PREDICTING THIOPURINE RESPONSE - The present invention relates to methods of predicting therapeutic efficacy of thiopurines in an individual by determining the presence of one or more risk variants. In one embodiment, the effective therapeutic efficacy of thiopurines is determined by the presence of risk variants at the genetic loci of HLA-DRB1, CREM, TAGAP, PLCL1, GPX4, SBNO2, MEF2A and/or LYSMD4. In another embodiment, the risk variants are located at the genetic loci of ARL4C, IL1R2, JAK2, 19q13, CARD9, SNAPC4, and/or 8q24. In another embodiment, the individual is has been diagnosed with inflammatory bowel disease. | 07-26-2012 |
20120196878 | METHODS OF OPTIMIZING DRUG THERAPEUTIC EFFICACY FOR TREATMENT OF IMMUNE-MEDIATED GASTROINTESTINAL DISORDERS - The present invention provides a method of optimizing therapeutic efficacy and reducing toxicity associated with 6-mercaptopurine drug treatment of an immune-mediated gastrointestinal disorder such as inflammatory bowel disease. The method of the invention includes the step of determining the level of one or more 6-mercaptopurine metabolites in the patient having an immune-mediated gastrointestinal disorder. | 08-02-2012 |
20120277256 | FREQUENCY MODULATED DRUG DELIVERY (FMDD) - Embodiments of the present disclosure include a coordination complex, comprising a first biologically active moiety, a second biologically active moiety, and a metal, wherein the first biologically active moiety and second biologically active moiety are bound to the metal by covalent coordination bonds, and wherein the first biologically active moiety and second biologically active moiety are different. These complexes may enhance the pharmacodynamic properties of biologically active moieties. | 11-01-2012 |
20130331403 | POLYMORPHIC FORMS OF 2-(5-BROMO-4-(4-CYCLOPROPYLNAPHTHALEN-1-YL)-4H-1,2,4-TRIAZOL-3-YLTHIO)ACE- TIC ACID AND USES THEREOF - Crystalline polymorph forms of 2-(5-bromo-4-(4-cyclopropyl naphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid are described. Pharmaceutical compositions and the uses of such compounds, compound forms, and compositions for the treatment of a variety of diseases and conditions are also presented. | 12-12-2013 |
20130345242 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF E1 ACTIVATING ENZYMES - This invention relates to compounds that inhibit E1 activating enzymes, pharmaceutical compositions comprising the compounds, and methods of using the compounds. The compounds are useful for treating disorders, particularly cell proliferation disorders, including cancers, inflammatory and neurodegenerative disorders; and inflammation associated with infection and cachexia. | 12-26-2013 |
20140303193 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF E1 ACTIVATING ENZYMES - This invention relates to compounds that inhibit E1 activating enzymes, pharmaceutical compositions comprising the compounds, and methods of using the compounds. The compounds are useful for treating disorders, particularly cell proliferation disorders, including cancers, inflammatory and neurodegenerative disorders; and inflammation associated with infection and cachexia. | 10-09-2014 |
20150065525 | METHODS FOR IMPROVING DIAPHRAGM FUNCTION - Provided are compositions and methods for improving diaphragm function in a patient by administering to the patient an effective amount of a skeletal muscle troponin activator or a pharmaceutically acceptable salt thereof. | 03-05-2015 |
20150313904 | TREATMENT OF CROHN'S DISEASE WITH DELAYED-RELEASE 6-MERCAPTOPURINE - Methods of treating patients suffering from Crohn's disease or ulcerative colitis who did not experience a clinical response to previous thiopurine administration, or suffered side effects from previous thiopurine administration, by administering a delayed release pharmaceutical composition comprising 6-mercaptopurine are disclosed. Methods of treating patients suffering from Crohn's disease or ulcerative colitis who are also being administered a steroid, 5-aminosalicylic acid, or an antibiotic by adjunctively administering a delayed release pharmaceutical composition comprising 6-mercaptopurine are also disclosed. | 11-05-2015 |